Lentiviral vector
Showing 1 - 25 of 734
P47-Phox, Deficiency of Trial in London (Lentiviral vector transduced CD34+ cells)
Not yet recruiting
- P47-Phox, Deficiency of
- Lentiviral vector transduced CD34+ cells
-
London, United KingdomGreat Ormond Street Hospital
Aug 2, 2022
Adenosine Deaminase Severe Combined Immune Deficiency Trial (A cryopreserved formulation of autologous mPB CD34+ hematopoietic
Not yet recruiting
- Adenosine Deaminase Severe Combined Immune Deficiency
- A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme
- (no location specified)
Jun 20, 2022
ß-thalassemia Trial (BD211)
Not yet recruiting
- β-thalassemia
- BD211
- (no location specified)
Mar 15, 2023
ß-thalassemia Trial in Shanghai (BD211)
Not yet recruiting
- β-thalassemia
- BD211
-
Shanghai, ChinaShanghai Ruijin Hospital
Mar 16, 2023
Severe Combined Immunodeficiency, X-Linked Trial in London (Lentiviral vector transduced CD34+ cells)
Recruiting
- Severe Combined Immunodeficiency, X-Linked
- Lentiviral vector transduced CD34+ cells
-
London, Greater London, United KingdomGreat Ormond Street Hospital for Children NHS Foundation Trust
Mar 15, 2022
Severe Combined Immunodeficiency Disease, X-linked Trial in San Francisco, Memphis, Seattle (genetic, drug, device)
Recruiting
- Severe Combined Immunodeficiency Disease, X-linked
- CL20-i4-EF1α-hγc-OPT
- +2 more
-
San Francisco, California
- +2 more
Jan 9, 2023
Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency Trial in Paris (ARTEGENE drug product)
Not yet recruiting
- Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency
- ARTEGENE drug product
-
Paris, FranceDepartment of Pediatric Immunology, Hematology and Rheumatology
Sep 26, 2022
Sickle Cell Disease Trial in Paris (DREPAGLOBE drug product)
Active, not recruiting
- Sickle Cell Disease
- DREPAGLOBE drug product
-
Paris, FranceDepartment of Biotherapy, Necker-Enfants Malades Hospital
Sep 26, 2022
Transfusion-dependent a-Thalassemia Trial (GMCN-508A Drug Product)
Not yet recruiting
- Transfusion-dependent α-Thalassemia
- GMCN-508A Drug Product
- (no location specified)
Feb 24, 2023
Hiv Trial in Philadelphia (Autologous CD4 T-Cells)
Completed
- Hiv
- Autologous CD4 T-Cells
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania
Nov 13, 2022
Fabry Disease Who Received Lentiviral Gene Therapy in Study
Enrolling by invitation
- Fabry Disease
- Safety and Efficacy Assessments
-
Melbourne, Parkville VIC, Australia
- +2 more
Oct 5, 2022
Cerebral Adrenoleukodystrophy (CALD) Trial in Worldwide (Lenti-D Drug Product (eli-cel))
Completed
- Cerebral Adrenoleukodystrophy (CALD)
- Lenti-D Drug Product (eli-cel)
-
Los Angeles, California
- +7 more
Mar 25, 2022
Mucopolysaccharidosis II Trial (Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII)
Not yet recruiting
- Mucopolysaccharidosis II
- Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII
- (no location specified)
Dec 16, 2022
Transfusion Dependent Beta-Thalassemia Trial in Nanning (GMCN-508B (LentiRed))
Recruiting
- Transfusion Dependent Beta-Thalassemia
- GMCN-508B (LentiRed)
-
Nanning, Guangxi, ChinaThe affiliated hospital of guangxi medical university
Feb 28, 2023
Hemophilia A Trial in Milwaukee (Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human
Recruiting
- Hemophilia A
- Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII
-
Milwaukee, WisconsinFroedtert Hospital and the Medical College of Wisconsin
Dec 21, 2022
Sickle Cell Disease Trial in Los Angeles (ßAS3-FB vector transduced peripheral blood CD34+ cells)
Recruiting
- Sickle Cell Disease
- βAS3-FB vector transduced peripheral blood CD34+ cells
-
Los Angeles, CaliforniaUniversity of California, Los Angeles (UCLA)
Apr 9, 2022
Sickle Cell Disease Trial in United States (bb1111)
Recruiting
- Sickle Cell Disease
- bb1111
-
Birmingham, Alabama
- +8 more
Jul 15, 2022
Wiskott-Aldrich Syndrome Trial in Atlanta, Milan (OTL-103)
Active, not recruiting
- Wiskott-Aldrich Syndrome
- OTL-103
-
Atlanta, Georgia
- +1 more
Sep 27, 2022
X-linked Severe Combined Immunodeficiency (XSCID) Trial run by the National Institute of Allergy and Infectious Diseases (NIAID)
Suspended
- X-linked Severe Combined Immunodeficiency (XSCID)
- Palifermin
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022
Mucopolysaccharidosis IH Trial in Milano (Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified
Active, not recruiting
- Mucopolysaccharidosis IH
- Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the α-L-iduronidase cDNA, in their final formulation medium.
-
Milano, ItalyOspedale San Raffaele
Aug 6, 2021
Sickle Cell Disease Trial in Los Angeles, Boston (single infusion of autologous bone marrow derived CD34+ HSC cells transduced
Active, not recruiting
- Sickle Cell Disease
- single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a
-
Los Angeles, California
- +1 more
Feb 8, 2022
Sickle Cell Disease Trial in United States (bb1111)
Active, not recruiting
- Sickle Cell Disease
- bb1111
-
Birmingham, Alabama
- +10 more
Dec 9, 2021